|
Michael (Mike) Milburn, Ph.D., Chief Scientific Officer, received his Ph.D. in structural chemistry at the University of California, Berkeley and was a research fellow at Harvard Medical School for his post-doctoral work. Before joining Metabolon, Dr. Milburn was senior vice president of research and corporate development at Sirtris Pharmaceuticals where he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration. Prior to Sirtris, Dr. Milburn was senior vice president of research at Plexxikon, Inc., responsible for the development of Plexxikon's proprietary high-throughput cocrystallography drug discovery platform. Dr. Milburn has over 15 years of experience in biotech and pharmaceutical companies including previous positions at Structural Genomix and GlaxoSmithKline | 